GoKawiil
Tech News
Insilico Medicine's AI-designed drug rentosertib, originally developed to treat idiopathic pulmonary fibrosis, produced unexpected reductions in biological age markers during a phase 2a trial. Researchers reanalyzed blood samples from 42 of 71 Chinese trial participants using six computational aging clocks, finding treated patients showed younger predicted ages after 12 weeks compared to placebo recipients.
US safety regulators have opened an investigation into how Tesla self-certified its Cybercab, a robotaxi that notably lacks a steering wheel and pedals. The probe examines whether Tesla's internal approval process for this unconventional vehicle design met required safety standards before deployment.
Alex Zhavoronkov, founder and co-CEO of AI-driven drug discovery company Insilico, is pursuing research suggesting that a treatment developed for fibrosis may have broader anti-aging effects. His work sits within a long personal and scientific interest in longevity research.